Generation of Human Stem Cell-Derived Pancreatic Organoids (POs) for Regenerative Medicine

Navarro-Tableros, Víctor; Gomez, Yonathan; Brizzi, Maria Felice; Camussi, Giovanni

doi:10.1007/5584_2019_340

Cited by 13 publications

(13 citation statements)

References 302 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This highlights the need for immunosuppressant-free strategies in islet transplanta-50 tion. One of these strategies involves encapsulation of islet cells within biocompatible semi-impermeable membranes or capsular devices, which create a physical and functional barrier between the graft and patient's immune cells, while simultaneously allowing the diffusion of oxygen and nutrients, and promoting favor-55 able insulin-secretion kinetics (reviewed in Navarro-Tableros V. et al, 2018 [7]). In human patients, however, this approach did not provide durable immunoprotection to the graft mainly because of membrane damage, instability of biomaterials used in construction of the device, and poor oxygen supply to the graft few selected patients with severe hypoglycemia or instable T1D.…”

Section: Introductionmentioning

confidence: 99%

Cell therapy for type 1 diabetes

Loretelli¹,

Assi²,

Seelam³

et al. 2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: Type 1 diabetes (T1D) is a lifelong condition resulting from autoimmune destruction of insulin-producing β-cells. Islet or whole-pancreas transplantation is limited by the shortage of donors and need for chronic immune suppression. Novel strategies are needed to prevent β-cell loss and to rescue production of endogenous insulin.Areas covered: This review covers the latest advances in cell-based therapies for the treatment and prevention of T1D. Topics include adoptive transfer of cells with increased immunoregulatory potential for β-cell protection, and β-cell replacement strategies such as generation of insulin-producing β-like cells from unlimited sources. Expert opinion: Cell therapy provides an opportunity to prevent or reverse T1D. Adoptive transfer of autologous cells having enhanced immunomodulatory properties can suppress autoimmunity and preserve β-cells. Such therapies have been made possible by a combination of genome-editing techniques and transplantation of tolerogenic cells. In-vitro modified autologous hematopoietic stem cells and tolerogenic dendritic cells may protect endogenous and newly generated β-cells from a patient's autoimmune response without hampering immune surveillance for infectious agents and malignant cellular transformations. However, methods to generate cells that meet quality and safety standards for clinical applications require further refinement.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell therapy for type 1 diabetes

Loretelli¹,

Assi²,

Seelam³

et al. 2020

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…The use of encapsulated-cell technology helps stem cells to avoid xenogeneic host immune attacks. Cell encapsulation refers to the enveloping of single or groups of cells in a polymeric biomaterial that forms membranes with semipermeable properties[ 1 , 34 , 35 ]. Miceli et al [ 34 ] encapsulated human amnion-derived MSCs in a semipermeable and biocompatible fiber so that the paracrine activity of these cells could promote tissue regeneration while it avoided allogenic-related problems[ 34 ].…”

Section: Problems and Solutions Of Xenogeneic Stem Cell Transplantationmentioning

confidence: 99%

“…Orive et al [ 35 ] demonstrated that stem cells could generate functional pancreatic organoids to treat type 1 diabetes mellitus, while gradual loss of function and cell death were commonly detected when pancreatic organoids were transplanted in immunocompetent animals. Macro- and/or micro-encapsulations are able to improve long-term survival of pancreatic organoids generated from human cells[ 1 , 35 ]. The referred research studies indicate that cell-encapsulated technology is an effective method to solve the immune rejection problem.…”

Section: Problems and Solutions Of Xenogeneic Stem Cell Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Xenogeneic stem cell transplantation: Research progress and clinical prospects

Jiang¹,

Li²,

Liu³

2021

WJCC

View full text Add to dashboard Cite

Organ transplantation is the ultimate treatment for end-stage diseases such as heart and liver failure. However, the severe shortage of donor organs has limited the organ transplantation progress. Xenogeneic stem cell transplantation provides a new strategy to solve this problem. Researchers have shown that xenogeneic stem cell transplantation has significant therapeutic effects and broad application prospects in treating liver failure, myocardial infarction, advanced type 1 diabetes mellitus, myelosuppression, and other end-stage diseases by replacing the dysfunctional cells directly or improving the endogenous regenerative milieu. In this review, the sources, problems and solutions, and potential clinical applications of xenogeneic stem cell transplantation will be discussed.

show abstract

“…Generation of beta cells basically requires close mimicking of the developmental programs of the organ that involve four stages in a culture dish: endoderm formation, posterior foregut formation, pancreatic progenitor cells and endocrine maturation (Navarro-Tableros et al 2019;Soltania et al 2019). Each stage is characterized by specific set of markers (Gradwohl et al 2000;Nelson et al 2007;Kelly et al 2011;Rezania et al 2013;Bonfanti et al 2015;Nostro et al 2015).…”

Section: Introductionmentioning

confidence: 99%

Development of islet organoids from human induced pluripotent stem cells in a cross-linked collagen scaffold

Sandilya

Singh

2021

Cell Regen

View full text Add to dashboard Cite

Islets organoids would have value in the cell replacement therapy for diabetes apart from usual personalized drug screening routes. Generation of a large number of Islets like clusters, with ability to respond to glucose stimulation appears to be an ideal choice. In this study we have generated islet organoids with the ability to respond to glucose stimulation by insulin release. The source of the cells was an iPSC cell line differentiated into the pancreatic progenitors. These cells were assembled in matrigel or cross-linked collagen scaffold and compared for their efficacy to release insulin upon stimulation with glucose. The assembled organoids were examined by immunohistochemistry and expression of the relevant marker genes. The organoids showed expression of islet like markers in both - matrigel and crosslinked collagen scaffold. The islet organoids in both the cases showed release of insulin upon stimulation with glucose. The crosslinked collagen scaffold is quite stable and supports islet cells growth and function.

show abstract

Generation of Human Stem Cell-Derived Pancreatic Organoids (POs) for Regenerative Medicine

Cited by 13 publications

References 302 publications

Cell therapy for type 1 diabetes

Cell therapy for type 1 diabetes

Xenogeneic stem cell transplantation: Research progress and clinical prospects

Development of islet organoids from human induced pluripotent stem cells in a cross-linked collagen scaffold

Contact Info

Product

Resources

About